Group 1 - The company signed an exclusive distribution agreement for Lidoderm® with Teikoku Pharma USA, Inc., granting exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm® is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The product is recognized in clinical guidelines for its effectiveness and safety in treating PHN and other neuropathic pain conditions, such as diabetic peripheral neuropathic pain [2][3] Group 2 - PHN is defined as pain persisting for one month or more after the healing of herpes zoster rash, with a significant prevalence among older adults, particularly those aged 60 and above [3] - The company aims to enhance its product portfolio with Lidoderm®, leveraging its brand advantages and existing marketing channels to create synergies and expand into new retail models [5] - The collaboration is expected to positively impact the company's operational performance and align with the interests of its shareholders [5] Group 3 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products in pain management and dermatology, producing over 200 prescription and over-the-counter products [4] - The demand for pain management solutions, particularly for PHN, is significant, and topical patches are well-recognized in the Chinese market for their direct and convenient application [4]
康哲药业(00867)：签订原研药Lidoderm利多卡因凝胶贴膏独家经销协议